Myriad Genetics (MYGN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Myriad Genetics (MYGN) PT Raised to $22 at Piper Jaffray
February 8, 2017 9:12 AM ESTPiper Jaffray analyst William Quirk reaffirms Neutral rating and raises price target on Myriad Genetics (NASDAQ: MYGN) to $22 (from $21), noting 2017 fiscal second quarter numbers for the company were strong, but near-term risks remain.
Quirk comments, "MYGN is up ~15% in aftermarket trading after... More
Ladenburg Thalmann Upgrades Myriad Genetics (MYGN) to Neutral
February 8, 2017 6:42 AM ESTLadenburg Thalmann upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $15.40 yesterday.
... More